Melissa Leichter: My Team Used AI to Pinpoint Likely Undiagnosed Patients with Glanzmann’s Thrombasthenia
Melissa Leichter, Rare Disease Executive at Novo Nordisk, shared on LinkedIn:
”I’ve had a number of conversations recently with commercial colleagues about AI, and we’re all struck by how dramatically it can change patient outcomes.
For people living with an undiagnosed disease, getting clarity on their condition can stretch on for years.
Their life quickly becomes a marathon of misdiagnoses, trying to find the right specialists, waiting for openings on those doctors’ schedules, insurance delays, and other hurdles to clear.
AI, with its ability to parse vast amounts of data and surface patterns that otherwise would remain hidden, can significantly shorten that painful journey.
I’ve seen this in action in a rare disease context.
My team used AI to pinpoint likely undiagnosed patients with Glanzmann’s Thrombasthenia, an ultra-rare platelet disorder, by analyzing a blend of diagnostic codes, medication usage, and procedure records.
We were able to illuminate complex data that could trigger an earlier intervention.
We need to do more to unleash AI as a tool in patient diagnosis, and the biggest obstacle to that is data fragmentation.
Health record systems rarely talk to each other, even within a single institution, resulting in disconnected pockets of patient information.
Moving forward, it’s essential that we invest in data connectivity and unified patient journeys.
Only then can machine learning help us shrink the timeline between debilitating symptoms and life-changing diagnoses at scale — and improve the lives of countless patients.”
Read the full article here.
Article: How Sanford Health Embeds AI into Its EHR to Catch Disease Earlier and Personalize Care
Authors: Katie Adams
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025